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Introduction: Sepsis is a dysregulated host response to infection with macro- and
microhemodynamic deterioration. Kynurenic acid (KYNA) is a metabolite of the
kynurenine pathway of tryptophan catabolism with pleiotropic cell-protective effects
under pro-inflammatory conditions. Our aim was to investigate whether exogenously
administered KYNA or the synthetic analog SZR-72 affects the microcirculation and
mitochondrial function in a clinically relevant rodent model of intraabdominal sepsis.
Methods: Male Sprague–Dawley rats (n = 8/group) were subjected to fecal peritonitis
(0.6 g kg−1 feces ip) or a sham operation. Septic animals were treated with sterile saline
or received ip KYNA or SZR-72 (160 µmol kg−1 each) 16 and 22 h after induction.
Invasive monitoring was performed on anesthetized animals to evaluate respiratory,
cardiovascular, renal, hepatic and metabolic dysfunctions (PaO2/FiO2 ratio, mean arterial
pressure, urea, AST/ALT ratio and lactate levels, respectively) based on the Rat Organ
Failure Assessment (ROFA) score. The ratio of perfused vessels (PPV) of the ileal serosa
was quantified with the intravital imaging technique. Complex I- and II-linked (CI; CII)
oxidative phosphorylation capacities (OXPHOS) and mitochondrial membrane potential
(19mt) were evaluated by High-Resolution FluoRespirometry (O2k, Oroboros, Austria) in
liver biopsies. Plasma endothelin-1 (ET-1), IL-6, intestinal nitrotyrosine (NT) and xanthine
oxidoreductase (XOR) activities were measured as inflammatory markers.
Results: Sepsis was characterized by an increased ROFA score (5.3 ± 1.3 vs.
1.3 ± 0.7), increased ET-1, IL-6, NT and XOR levels, and decreased serosal PPV
(65 ± 12% vs. 87 ± 7%), 19mt and CI–CII-linked OXPHOS (73 ± 16 vs. 158 ± 14, and
189 ± 67 vs. 328 ± 81, respectively) as compared to controls. Both KYNA and SZR-72
reduced systemic inflammatory activation; KYNA treatment decreased serosal perfusion
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heterogeneity, restored PPV (85 ± 11%) and complex II-linked OXPHOS (307 ± 38),
whereas SZR-72 improved both CI- and CII-linked OXPHOS (CI: 117 ± 18;
CII: 445 ± 107) without effects on PPV 24 h after sepsis induction.
Conclusion: Treatment with SZR-72 directly modulates mitochondrial respiration,
leading to improved conversion of ADP to ATP, while administration of KYNA restores
microcirculatory dysfunction. The results suggest that microcirculatory and mitochondrial
resuscitation with KYNA or the synthetic analog SZR-72 might be an appropriate
supportive tool in sepsis therapy.
Keywords: polymicrobial sepsis, kynurenic acid, N-methyl-D-aspartate receptor antagonist, microcirculation,
mitochondrial respiration, organ dysfunction
INTRODUCTION
Treatment of sepsis-induced multi-organ failure (MOF) is one
of the most challenging tasks in intensive care therapy (1).
According to current knowledge, the key problem in sepsis is
the oxygen extraction deficit, which can originate from either
insufficient oxygen delivery to the cells or inability of the
cells to utilize oxygen. The poorly functioning microvasculature
reduces delivery of oxygen to the tissue. In addition, as the
mitochondrial electron transport system (ETS) is insufficient,
it is unable to use oxygen efficiently; the switch to anaerobic
pathways thus causes an energy deficit and eventual cell
death (2, 3). These processes are intimately linked and finally
lead to microcirculatory and mitochondrial distress syndrome
(MMDS), which is believed to mediate end-organ damage
(4). Therefore, the cornerstone of current organ-protective
therapies is to prevent and treat oxygen debt globally by
increasing oxygen uptake and transport, providing an adequate
supply to meet subcellular oxygen demand (5). However,
currently used respiratory- and circulatory-supportive modalities
cannot always improve sepsis-induced alterations at the later
stages (6).
Given this background, the major goal of our study was to
find a novel, clinically applicable maneuver for microcirculatory
recruitment and mitochondrial resuscitation to minimize the
energy deficit of the organs. The metabolites and end-products
of the tryptophan–L-kynurenine pathway have already been
implicated in several ischemic and inflammatory disorders
in the central nervous system (7). This pathway generates
excitotoxic, N-methyl-D-aspartate receptor (NMDA-R) agonist
quinolinic acid and the glutamate receptor antagonist kynurenic
acid (KYNA). Interestingly, sepsis-induced tissue hypoxia is
also associated with the activation of NMDA-R, which can
lead to glutamate excitotoxicity and oxidative/nitrosative stress-
mediated cell damage (8). Further, elevated plasma KYNA
levels have been reported in association with pro-inflammatory
cytokines and increased lactate concentrations in septic shock
patients (9).
Excessive NMDA-R activation has been documented in
various experimental models of inflammatory bowel diseases
(10). Apart from neurons, the expression of receptor subunits
was confirmed in peripheral organs, including the heart, small
intestine, pancreas, and liver (11), where the activation of
cellular NMDA-Rs may initiate oxidative stress, mitochondrial
dysfunction, and apoptosis through calcium (Ca2+)- and reactive
oxygen species (ROS)-mediated pathways (12).
Based on these findings, we hypothesized that KYNA via
the inhibition of NMDA-R or other mechanisms might be a
therapeutic tool to reduce microcirculatory and mitochondrial
disturbances in sepsis. KYNA has a high affinity for the
glycine co-agonist site on NMDA-R, binds to orphan G
protein-coupled receptor GPR35 and aryl hydrocarbon
receptor (13), and therefore takes part in the modulation
of glutamatergic neurotransmission and alleviates adaptive
immune response. Despite these properties and pleiotropic
effects, its role in the regulation of the circulatory system
is still unclear, and KYNA is considered a non-receptor-
specific molecule (14). To address this issue, we set out
to characterize and compare the microcirculatory and
mitochondrial effects of KYNA and its blood–brain barrier
(BBB)-permeable synthetic analog, SZR-72 (15, 16), on sepsis-
induced microcirculatory and mitochondrial abnormalities




Male Sprague–Dawley rats (n = 32; 350 ± 30 g) were used. The
animals were housed in plastic cages (21–23◦C) with a 12/12 h
dark/light cycle and access to standard rodent food and water
ad libitum. The experiments were performed in accordance with
the National Institutes of Health guidelines on the handling and
care of experimental animals and the EU Directive 2010/63 for
the protection of animals used for scientific purposes (approval
number V/175/2018).
Sepsis Induction
Polymicrobial sepsis was induced with 3ml intraperitoneally
(ip)-administered fecal inoculum as described before (17).
Briefly, fresh feces was collected from different animals and
suspended in physiological saline. The concentration of the
microorganisms in the suspension was determined before
injection in 0.6 g kg−1 final doses.
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Experimental Protocol
The animals were randomly divided into sham-operated (n =
8) and sepsis (n = 24) groups. Septic animals were subjected
to fecal peritonitis (0.6 g kg−1 feces ip) or a sham operation
(sterile saline ip). After 6 and 16 h from sepsis induction, all
the animals received balanced crystalloid solution (Ringerfundin,
1.5ml kg−1; B. Braun, Melsungen, Germany) and analgesics
(Buprenorphine, 15 µg kg−1; Richter Pharma, Hungary)
subcutaneously. Septic animals were divided further into KYNA-
(Sigma-Aldrich Inc., St. Louis, MO, USA; 160 µmol kg−1 ip;
n = 8) or SZR-72- [2-(2-N,N-dimethylaminoethyl-amine-1-
carbonyl)-1H-quinolin-4-one hydrochloride, synthesized by the
Institute of Pharmaceutical Chemistry, University of Szeged,
Hungary; 160 µmol kg−1 ip; n = 8] treated and vehicle-treated
control (saline ip; n = 8) groups. Treatments were performed in
two steps (80 µmol kg−1; in 1ml kg−1 saline each) 16 and 22 h
after sepsis induction.
To follow the progression of sepsis, the health status of
the animals was monitored with a standardized well-being
scoring system originally described for mice (18, 19). At the
22nd hour of the study, all the animals were anesthetized (ip
ketamine 45.7mg kg−1 and xylazine 9.12mg kg−1) and placed
on a heating pad to maintain normal core body temperature
(37◦C). A tracheostomy was performed to facilitate spontaneous
breathing, and the right jugular vein was cannulated for fluid
resuscitation (Ringerfundin, 10 ml−1 kg−1 h−1; B. Braun,
Melsungen, Germany) and for the maintenance of continuous
anesthesia (ketamine 12mg kg−1 h−1, xylazine 2.4mg kg−1 h−1,
and diazepam 0.576mg kg−1 h−1 iv). The left carotid artery was
cannulated tomonitor heart rate (HR) andmean arterial pressure
(MAP) (SPEL Advanced Cardiosys 1.4; Experimetria Ltd.,
Budapest, Hungary).
After surgery and a 30-min stabilization, MAP and HR
monitoring was performed every 15min for 60min. Arterial
and venous blood gas analyses (Cobas b123; Roche Ltd., Basel,
Switzerland) were performed at the 0th and 60th min of the
monitoring period. Simplified oxygen extraction (O2ER) was
calculated from arterial and venous oxygen saturation based on
a standard formula (SaO2 – SvO2)/SaO2). The degree of lung
injury was determined by using the arterial partial pressure of
oxygen to fractional inspired oxygen (PaO2/FiO2) ratio. After the
60-min hemodynamic monitoring period, a median laparotomy
was performed to observe the microcirculation of the ileal
serosa (see below). Thereafter, a liver tissue biopsy was taken
to evaluate mitochondrial respiratory functions. Samples from
the terminal ileum were harvested, followed by blood sampling
from the inferior vena cava for biochemical measurements (see
below). After tissue samplings, animals were sacrificed under
deep anesthesia (Figure 1).
Measurements of Metabolic, Inflammatory,
and Organ Function-Related Markers
Whole blood lactate levels were measured from venous blood
samples (Accutrend Plus Kit; Roche Diagnostics Ltd., Rotkreuz,
Switzerland) to determine metabolic imbalance. After the
liver sampling, blood samples were collected from the inferior
caval vein into precooled, EDTA-containing tubes (1mg
ml−1), centrifuged (1,200g at 4◦C for 10min), and stored at
−70◦C. Plasma endothelin-1 (ET-1) and interleukin-6 (IL-6)
levels were determined with standard ELISA kits (Cusabio
Biotechnology Ltd., Wuhan, China and Biomedica Ltd., Vienna,
Austria, respectively) following the manufacturer’s instructions.
Kidney injury was determined from plasma urea level, whereas
liver dysfunction was assessed by measuring plasma alanine
aminotransferase (ALT) and aspartate aminotransferase
(AST) levels, using a Roche/Hitachi 917 analyzer (F.
Hoffmann-La Roche AG, Switzerland). The De Ritis ratio
(AST/ALT ratio) was calculated as a marker of hepatocellular
damage. All analyses were performed on coded samples in a
blinded fashion.
Evaluation of Ileal Xanthine
Oxidoreductase Activity and Nitrotyrosine
Levels
The same snap frozen tissues were used for these measurements.
Ileum biopsies kept on ice were homogenized with a rotor
stator homogenizer in a phosphate buffer (pH 7.4) containing
50 mmol l−1 Tris–HCl, 0.1 mmol l−1 EDTA, 0.5 mmol l−1
dithiothreitol, 1 mmol l−1 phenylmethylsulfonyl fluoride, 10
µg ml−1 soybean trypsin inhibitor, and 10 µg ml−1 leupeptin.
Homogenates were then centrifuged at 4◦C for 10min at
15,000g, and the supernatant was then divided into one
ultra-filtered part and one unfiltered one, which were used
for xanthine oxidoreductase (XOR) activity and nitrotyrosine
determination, respectively.
XOR activity was measured in the ultra-filtered supernatant
(Amicon Ultra-0.5 Centrifugal Filter) with a fluorometric
kinetic assay on the basis of the conversion of pterin to
isoxanthopterin in the presence (total XOR) or absence (xanthine
oxidase activity) of the electron acceptor methylene blue
(20). XOR activity was calculated and expressed in µmol
min−1 mg protein−1.
Free nitrotyrosine as a marker of peroxynitrite generation
was measured from unfiltered supernatant by enzyme-linked
immunosorbent assay (Cayman Chemical, Ann Arbor, MI,
USA). The supernatants were incubated overnight with anti-
nitrotyrosine rabbit IgG and nitrotyrosine acetylcholinesterase
tracer in precoated (mouse anti-rabbit IgG) microplates,
followed by development with Ellman’s reagent, and measured
spectrophotometrically at 405 and 420 nm. Tissue nitrotyrosine
content was calculated in ng mg−1 protein. Protein content was
assessed by Lowry’s method.
Rat Organ Failure Score Assessment
The severity of organ failure was determined by using a scoring
system adapted for rats (Rat Organ Failure Assessment—ROFA)
considering the principles of the Sepsis-3 international consensus
(Table 1). ROFA components were scored between 0 and 4
based on threshold values of different parameters (21). The
cardiovascular (MAP values) and respiratory components (the
PaO2/FiO2 ratio) of ROFA were determined from readings of
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FIGURE 1 | The experimental scheme. The animals were randomly assigned into the sham-operated and sepsis groups. Sixteen hours after sepsis induction, animals
were randomly divided into three subgroups: treated with vehicle, KYNA (80 + 80 µmol kg−1 ip), or SZR-72 (80 + 80 µmol kg−1 ip), respectively.
hemodynamic and blood gas monitoring, respectively. Sepsis-
induced liver damage was determined by calculating the
AST/ALT ratio (De Ritis ratio) (22). Renal dysfunction was
characterized by determining plasma urea levels. The ROFA
scoring system was supplemented by scoring the degree of blood
lactate level (indicative of metabolic disturbances caused by tissue
hypoxia). The ROFA values were calculated by summing up the
scores in each element of the scoring system. Septic status was
defined as a ROFA score above 2.
Microcirculatory Measurements
The Incident Dark Field (IDF) imaging technique (CytoCam
Video Microscope System; Braedius Medical, Huizen, the
Netherlands) was used for non-invasive evaluation of the
serosal microcirculation of the ileum. IDF imaging is optimized
for visualization of hemoglobin-containing structures by
illuminating the organ surface with linearly polarized light,
where the filtered light reflected from the tissues is detected
by a computer-controlled sensor (23). Images from an ileum
segment were recorded in six, 50-frame-long, high-quality video
clips (spatial resolution 14 megapixels; temporal resolution
60 fps). The video was recorded at separate locations of the
terminal ileum by the same investigator. The records were saved
as digital AVI-DV files to a hard drive and analyzed with an
off-line software-assisted system (AVA 3.0, Automated Vascular
Analysis, Academic Medical Center, University of Amsterdam).
The screens recorded with the IDF imaging technique were
divided into four equal quadrants, as recommended. The
TABLE 1 | Threshold values of the Rat Organ Failure Assessment (ROFA) scoring
























<1.7 1.7–2.5 >2.5 – –
Metabolism Lactate
(mmol l−1)
<1.64 1.64–3 3–4 4–5 >5
ROFA, Rat Organ Failure Assessment; MAP, mean arterial pressure; ALT, alanine
aminotransferase; AST, aspartate aminotransferase.
proportion of perfused vessels (PPV) was defined as the
ratio of the perfused vessel lengths to total vessel lengths.
The PPV values were calculated in all quadrants, and the
software (Automated Vascular Analysis 3.0) for the device
provided four individual PPV values, Q1 PPV, Q2 PPV,
Q3 PPV, and Q4 PPV, respectively. The average of these
individual values (Q1PPV–Q4PPV) is shown as % PPV in
the illustrations.
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The median PPV values for the four quadrants were used as a
reference (median values for Q1–4) in calculating microvascular
heterogeneity (MVH). Heterogeneity was defined as the average
difference of the PPV values (%) between each quadrant and the
reference value (the differences are given in absolute values) for
each record using the following formula:
MVH = [|(M∑QPPV − Q1PPV)|
+|(M∑QPPV − Q2PPV)| + |(M
∑
QPPV − Q3PPV)|
+|(M∑QPPV − Q4PPV)|]/number of quadrants
M=median
M∑QPPV =median of the total PPV in the four quadrants
QxPPV= PPV value for each individual quadrant.
This calculation provides numerical values for perfusion
heterogeneity (24, 25).
Measurement of Mitochondrial Respiration
and Membrane Potential
Mitochondrial O2 consumption and mitochondrial membrane
potential (19mt) were assessed from liver homogenates
using High-Resolution FluoRespirometry (Oxygraph-2k;
Oroboros Instruments, Innsbruck, Austria). Measurements were
performed in a Mir05 respiration medium under continuous
magnetic stirring at 37◦C. Changes in 19mt were assessed
with safranin dye using Blue Fluorescence Sensor (Sigma
Aldrich, St. Louis, MO, USA). DatLab software (Oroboros
Instruments, Innsbruck, Austria) was employed for online
display, respirometry data acquisition, and analysis. A detailed
description of the FluoRespirometry protocol used can be found
in the Supplementary Data 1.
Statistical Analysis
Data analysis was performed with a statistical software package
(SigmaStat for Windows; Jandel Scientific, Erkrath, Germany).
Normality of data distribution was analyzed with the Shapiro–
Wilk test. The Friedman analysis of variance on ranks was
applied within groups. Time-dependent differences from the
baseline for each group were assessed with Dunn’s method. In
this study, differences between groups were analyzed with the
Kruskal–Wallis one-way analysis of variance on ranks, followed
by Dunn’s method. Median values and 75th and 25th percentiles
are provided in the figures; P < 0.05 were considered significant.
RESULTS
Hemodynamics and Oxygen Dynamics
Sepsis resulted in significant hypotension during the observation
period, which was not altered by the treatments (Figure 2A).
HR increased significantly in two time points (the 0th and
30th min of the monitoring period) in the SZR-72-treated
group (Figure 2B). As compared with sham-operated animals, a
decreased PaO2/FiO2 ratio was observed in the vehicle-treated
sepsis group, whereas no significant changes were found in
the other groups (Figure 2C). Sepsis reduced O2ER values as
compared with the sham-operated group, whereas both KYNA
and SZR-72 resulted in a significant improvement in this
parameter (Figure 2D).
Changes in Metabolic and Organ
Dysfunction Markers
In the vehicle-treated sepsis group, plasma urea levels
significantly increased, but urea levels in both treated groups
were similar to those seen in the sham animals (Figure 3A).
Hepatic cellular damage as indicated by the De Ritis ratio was
evident in the vehicle-treated and SZR-72-treated sepsis groups,
whereas this ratio did not differ between the sham-operated and
KYNA-treated animals (Figure 3B). When ALT and AST values
were evaluated separately (Supplementary Figures 1A,B), these
changes were not influenced by the treatments. In comparison
with the sham-operated group, all of the groups challenged with
sepsis showed a similar extent of elevation in blood lactate levels
(Figure 3C). The ROFA score was significantly higher in the
vehicle-treated and SZR-72-treated sepsis groups than in the
sham-operated group. The ROFA values in the KYNA-treated
group were not significantly different from those in the septic
group (Figure 3D).
Changes in Inflammatory and
Oxidative/Nitrosative Stress Markers
Sepsis led to significant elevations in ET-1, IL-6, nitrotyrosine
levels, and XOR activity (Figures 4A–D). All of these parameters
remained, however, at the levels seen in the sham group in both
the sepsis+ KYNA and sepsis+ SZR-72 groups.
Microcirculatory Changes
Sepsis-induced microcirculatory perfusion disorders manifested
in lower levels of capillary perfusion and increased perfusion
heterogeneity as compared with those in the sham group
(Figures 5A,B). The values of these parameters did not differ
between the sepsis and sepsis + SZR-72 groups and between the
sham and sepsis + KYNA groups. KYNA was significantly more
effective in ameliorating sepsis-related changes than SZR-72.
Changes in Mitochondrial Respiration
Baseline respiration without external substrate (BLresp) and
respiration following the oxidation of complex I- and complex
II-linked substrates (LEAKGM and LEAKS) were significantly
decreased in sepsis (Figures 6A,B). KYNA administration did
not modify sepsis-induced changes in BLresp, LEAKGM, and
LEAKS. In this respect, treatment with SZR-72 preserved
mitochondrial respiration with and without NADH- and
FADH2-linked substrates (Figures 6A,B). In addition, sepsis
significantly decreased complex I- and complex II-linked
OXPHOS. Both KYNA and SZR-72 increased complex II-
linked OXPHOS capacity, whereas SZR-72 was able to restore
complex I-linked OXPHOS completely (Figure 6A). As a result
of septic insult, respiratory acceptor control ratios (RCR I
and RCR II) were markedly decreased. These parameters were
significantly improved by KYNA and completely reversed by
SZR-72 treatment (Figures 6A,B).
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FIGURE 2 | Time-dependent changes in mean arterial pressure (A), heart rate (B), PaO2/FiO2 ratio (C), and oxygen extraction (D) in the sham-operated group (empty
box) and in the different sepsis groups treated with the saline vehicle (black box), KYNA (gray diamond/striped gray box), and SZR-72 (dark gray diamond with
cross/checked gray box). The plots demonstrate the median values (horizontal line in box plots) and the 25th (lower whisker) and 75th (upper whisker) percentiles. xP
< 0.05 vs. sham-operated; #P < 0.05 vs. vehicle-treated sepsis; *P < 0.05 vs. 0min.
Changes in Mitochondrial Membrane
Potential (19mt)
The addition of complex II substrate resulted in a sharp
decrease in fluorescence signal (FLEAK) within 90 s, indicating
an increase of 19mt (succinate-induced hyperpolarization)
(Figure 7A). As a result of the septic insult, there was a
comparatively lower decrease in safranin fluorescence after
succinate (Figure 7B), reflecting a significant decrease in 19mt.
Treatment with KYNA markedly improved, whereas SZR-72
completely restored the sepsis-induced decrease in 19mt.
Stimulation with CCCP resulted in depolarization and collapse of
19mt at a critical uncoupler concentration. These changes were
characterized as (I) stepwise increases in safranin fluorescence
(depolarization) and (II) stabilization of fluorescence signal
(loss of 19mt).
In comparison with the sham-operated group, CCCP-
mediated loss of 19mt was obtained at lower uncoupler
concentration in the vehicle-treated septic group (Figure 7B).
KYNA and SZR-72 therapies significantly increased the
concentration of CCCP used for 19mt disruption. Among
these treatments, SZR-72 had a more profound effect on 19mt
preservation (Figures 7A,B).
DISCUSSION
The present study demonstrates the distinct effects of KYNA and
its synthetic analog on microcirculation and mitochondrial
function in experimental sepsis. Proper analgesia, fluid
resuscitation, and assessment of organ failure were conducted
according to the standards in the Minimum Quality Threshold
in Pre-clinical Sepsis Studies (MQTiPSS) guidelines (19).
The clinical relevance of this model was confirmed by the
presence of hypotension, impaired pulmonary function and
oxygen extraction, and elevations in lactate levels and in
oxidative/nitrosative stress as well as microcirculatory and
mitochondrial dysfunctions. Sepsis-induced organ injuries were
characterized by a newly developed, rat-specific organ failure
(ROFA) scoring system based on threshold values adopted from
the relevant literature (21). The scoring system included the
following: (I–II) cardiovascular and respiratory dysfunctions
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FIGURE 3 | Changes in plasma urea (A), De Ritis ratio (AST/ALT) (B), whole blood lactate levels (C), and ROFA score values (D) in the sham-operated group (empty
box) and in the different sepsis groups treated with the saline vehicle (black box), KYNA (striped gray box), and SZR-72 (checked gray box). The plots demonstrate the
median (horizontal line in the box) and the 25th (lower whisker) and 75th (upper whisker) percentiles. Between groups: Kruskal–Wallis test and Dunn’s post-hoc test.
xP < 0.05 vs. sham-operated.
were determined by MAP and PaO2/FiO2 values, respectively.
(In MAP scoring, anesthesia-related effects were also taken
into account, whereas PaO2/FiO2 was used in accordance with
clinical practice.) (III) The AST/ALT ratio was considered
to assess hepatocellular damage based on the observation
that AST depicts liver-related injury more specifically than
ALT (22). (IV) Renal damage was characterized by plasma
urea changes (26) based on threshold values suggested by
Zhai et al. (21). (V) The ROFA score was supplemented
with consideration of lactate values (indicative of cellular
hypoxia) according to Zhai et al. (21). This novel, rat-specific
scoring system was applicable to trace development of MOF
in this rat sepsis model and indicated differences between
the efficacy of KYNA and SZR-72. Both treatments reduced
lung and kidney dysfunctions to a similar extent due to the
decreased level of inflammatory markers and their enhanced
antioxidant/anti-nitrosative effect. However, only KYNA
treatment reduced hypoxia-sensitive ET-1 levels, also displaying
a tendency toward amelioration of liver injury and ROFA
score values.
Deteriorating tissue perfusion is a key element in sepsis
pathophysiology and in the development of MOF (4). We
observed that both KYNA and SZR-72 prevented a sepsis-
induced decrease in oxygen extraction to the same extent,
but only KYNA ameliorated sepsis-related microcirculatory
perfusion deficit (reduction in capillary perfusion and an increase
in perfusion heterogeneity) significantly. This distinct effect of
compounds is possibly due to their different structure- and
receptor-related characteristics (27).
The potential direct microcirculatory effects of KYNA in the
ileum are unknown, but it has been shown to increase global
and cortical renal blood flow (and to improve renal excretion)
under physiological conditions and to reduce renal oxidative
stress during ischemia–reperfusion injury (28, 29). Based on our
results, some of these micro-hemodynamic effects can also be
linked to a reduced ET-1 release elicited by KYNA.
NMDA receptor-related microcirculation improvement can
be explained by many mechanisms. Firstly, antagonism of
NMDA receptors expressed on the surface of smoothmuscle cells
brings about reduced intracellular Ca2+ levels (30), resulting in
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FIGURE 4 | Changes in plasma endothelin-1 (ET-1) (A), interleukin-6 (IL-6) (B), ileal nitrotyrosine levels (C), and xanthine oxidoreductase (XOR) activity (D) in the
sham-operated group (empty box) and in the different sepsis groups treated with saline (black box), KYNA (striped gray box), and SZR-72 (checked gray box). The
plots demonstrate the median (horizontal line in the box) and the 25th (lower whisker) and 75th (upper whisker) percentiles. Between groups: Kruskal–Wallis test and
Dunn’s post-hoc test. xP < 0.05 vs. sham-operated; #P < 0.05 vs. vehicle-treated sepsis.
FIGURE 5 | Changes in the proportion of perfused vessels (A) and in perfusion heterogeneity values (B) in the serosal layer of the ileum in the sham-operated group
(empty box) and in the different sepsis groups treated with saline (black box), KYNA (striped gray box), and SZR-72 (checked gray box). The plots demonstrate the
median (horizontal line in the box) and the 25th (lower whisker) and 75th (upper whisker) percentiles. Between groups: Kruskal–Wallis test and Dunn’s post-hoc test.
xP < 0.05 vs. sham-operated; #P < 0.05 vs. vehicle-treated sepsis; §P < 0.05 sepsis + KYNA vs. sepsis + SZR-72.
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FIGURE 6 | Baseline respiration, substrate oxidation (LEAKGM and LEAKS ), complex I- (A) and complex II-linked (B) OXPHOS capacities (OXPHOS I and OXPHOS II;
left axis), and respiratory acceptor control ratios (CI, CII RCR; right axis) in the sham-operated group (empty box) and in the different sepsis groups treated with the
saline vehicle (black box), KYNA (striped gray box), and SZR-72 (checked gray box). The plots illustrate the median (horizontal line in the box) and the 25th (lower
whisker) and 75th (upper whisker) percentiles. XP < 0.05 vs. sham-operated; #P < 0.05 vs. vehicle-treated sepsis; §P < 0.05 sepsis + KYNA vs. sepsis + SZR-72.
FIGURE 7 | Succinate-induced hyperpolarization (A) and CCCP-induced loss of mitochondrial membrane potential (B) in the sham-operated group (empty box) and
in the different sepsis groups treated with the saline vehicle (black box), KYNA (striped box), and SZR-72 (checked box). The plots illustrate the median (horizontal line
in the box) and the 25th (lower whisker) and 75th (upper whisker) percentiles. xP < 0.05 vs. sham-operated; #P < 0.05 vs. vehicle-treated sepsis; §P < 0.05 sepsis
+ KYNA vs. sepsis + SZR-72.
smooth muscle relaxation (31). On the other hand, a reduction
of the levels of pro-inflammatory IL-6, XOR activity, and ROS-
sensitive vasoconstrictor ET-1 release by KYNA may attenuate
the cytokine- and ROS-induced vasoconstriction of microvessels.
Although the use of vasodilator therapy in sepsis is debated
(6, 32, 33), a reduction of circulating ET-1 levels through a
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combined ETA/ETB receptor-targeted treatment regimen has
been demonstrated to ameliorate microcirculatory deficit in
sepsis (17).
Further, KYNA may also act as an agonist for the orphan
receptor GPR35 and reduce inflammation independently of the
NMDA receptors. This receptor is expressed at high levels
in intestine and immune cells (34), and the concentrations
of KYNA required to induce effects differ between NMDA-R
and GPR35. Compared with NMDA-R, lower concentrations of
KYNA are able to elicit a response when binding to GPR35
(35). Taking into account that (1) KYNA is an endogenous
ligand for GPR35 and that (2) only KYNA, but not the
synthetic analog, was able to restore the perfusion disturbances
in the ileum, a GPR35-mediated mechanism cannot be
ruled out.
The KYNA- and its analog-based treatments also had different
effects on mitochondrial function, with the ameliorating effects
of SZR-72 being more pronounced. A considerable decrease in
substrate- and ADP-stimulated respirations was accompanied by
a decrease in RCR and 19mt after sepsis insult (17). A decrease
of 19mt may originate in complex metabolic, functional,
and membrane integrity changes within the organelle and
may explain the decline in mitochondrial O2 consumption
and lower interdependence (coupling) of ATP synthesis with
ETS. Although an O2-independent glycolytic pathway for ATP
production has been documented, this alternate route may not be
effective for energy production in sepsis. Of note, ATP depletion
is not a unique component of sepsis-induced mitochondrial
dysfunction; organellar ROS production, elevated mitochondrial
DNA level, transition pore opening-mediated apoptosis, and
necrosis are fundamental mitochondrial events, which lead to
cellular injury (36, 37). In addition, the release of mitochondrial
components of damage-associated molecular patterns to the
extracellular space may further aggravate an inflammatory
response (38). Taken together, all these processes are
intimately involved in the progression of sepsis and contribute
to MOF.
The role of endogenous KYNA on mitochondrial physiology
is still unmapped; however, exogenous KYNA was able to
improve OXPHOS II and 19mt without affecting OXPHOS
I. This difference in complex activities may arise from the
fact that complex I is more susceptible to cellular injury
than complex II. Oxidation of glutamate requires pyridine
nucleotides, and these with other cofactors may be lost during
sepsis (39).
Our findings are in agreement with the study by Ferreira
et al. (40), in which KYNA ameliorated several aspects of
mitochondrial function in a neurodegeneration model. Similar
to our results, KYNA administration significantly improved
succinate dehydrogenase activity and 19mt. In addition, KYNA
preserved mitochondrial mass, enhanced antioxidant enzyme
levels, and reduced ROS production after quinolinic acid-
induced cell injury (40). In adipose tissue, KYNA modulated
energy utilization (increased lipid metabolism andmitochondrial
respiration) via a GPR35 pathway (41).
In our experiments, administration of SZR-72 markedly
improved the key indices of mitochondrial function. Previous
studies with the KYNA analog revealed a more pronounced anti-
inflammatory response in animal models of colitis and neuro-
inflammation than that seen with KYNA (10, 16, 42), but both
KYNA and SZR-72 reduced oxidative/nitrosative stress marker
levels [XOR, nitric oxide synthase (NOS), and myeloperoxidase
(MPO) activities] (10) and attenuated glutamate expression
(42). Compared with KYNA, the effects of SZR-72 were
more pronounced in this sepsis model, and a remarkable
increase in ADP-stimulated respirations (OXPHOS I and II),
RCR, and 19mt was found in liver homogenate after sepsis
induction. Preservation of these parameters is fundamental
for better O2 utilization (less ETS-linked ROS is generated),
maintenance of ATP production, and provision of 19mt for
mitochondrial transport.
Several hypotheses may explain the mechanism behind the
more advantageous mitochondrial effects of SZR-72. First,
the physico-chemical properties of KYNA and SZR-72 are
different, thus possibly influencing crossing through the BBB
and membranes (16). There is evidence that KYNA only crosses
the BBB poorly, whereas SZR-72 is BBB-permeable due to a
water-soluble side chain with an extra cationic center (7, 43).
Apart from BBB, a facilitated membrane crossing of SZR-72
may affect intracellular signaling, including the activation of
antioxidative/anti-apoptotic pathways.
A second scenario is a distinct molecule binding at the
NMDA-R glycine site. More recently, NMDA-Rs were shown to
be present in the inner mitochondrial membrane (mtNMDA-R)
(44), where they may play a regulative role in (1) Ca2+ transport,
(2) ROS production, and (3) metabolic switching during hypoxia
(45). Under these circumstances, it may well be that SZR-72 has a
much higher affinity for either plasma membrane or mtNMDA-
R than KYNA. In addition, a protein–protein interaction between
NMDA-R and an ND2 subunit of complex I was found through
an Src adapter protein (12). It cannot be ruled out that KYNA
and SZR-72 influence this interaction and regulate mitochondrial
homeostasis differently.
The influence of sepsis on NMDA-R expression and glutamate
levels is incompletely characterized. We did not examine changes
in NMDA-R subunits due to technical limitations, but other
laboratories have found a marked increase in lung NR1 and
NR2A contents in a cecal ligation and puncture (CLP) sepsis
model. Furthermore, treatment with the NMDA-R antagonist
MK-801 lowered lactate dehydrogenase and oxidative damage
and improved survival 144 h after sepsis induction in rats (46).
Similarly, survival wasmarkedly increased (by 80%), andmarkers
of inflammation were reduced in MK-801-treated mice 48 h after
lipopolysaccharide (LPS) stimuli (47). In this model, LPS also
raised the glutamate level in bronchoalveolar lavage fluid. Based
on these findings and the fact that KYNA is a natural antagonist,
a similar, NMDA-R-linked mechanism, at least in part, cannot be
ruled out in our polymicrobial sepsis model.
Our study has limitations. Firstly, the observation timeline
was relatively short, and therefore longer end points, such as
mortality, with longer pharmacological effects should also be
examined in follow-up studies. Our newly described ROFA score
also seems to be a potentially useful tool for this purpose, but it
will be necessary to validate the system under other experimental
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conditions as well. The effect of the ketamine-containing
anesthesia on the results cannot be disregarded. Similarly, despite
our intention to follow all of the recommendations in the
MQTiPSS guidelines, antimicrobial therapy was excluded from
the protocol due to the known influence on mitochondrial
respiration (48).
In conclusion, both treatments with KYNA and its
synthetic analog attenuated the deleterious consequences of
oxidative/nitrosative stress and resulted in lower inflammatory
mediator release. Administration of SZR-72 may directly
regulate mitochondrial respiration and ATP synthesis, whereas
treatment with KYNA primarily ameliorates microcirculatory
dysfunction and consequently restores organelle function.
Further experiments are surely needed to clarify the exact
mechanism behind these compounds, but these results suggest
that therapies with KYNA or its synthetic analog, SZR-72, against
MMDS might be a supportive intervention in the treatment
of sepsis.
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